President and Chief Executive Officer
Mr. Ogier co-founded Acetylon Pharmaceuticals in October 2008 and was appointed its founding President and Chief Executive Officer and a Director of the company in July 2009 at the time of its Series A financing. Mr. Ogier has raised more than $150 million in private and public company financing during his 20+ year life science industry career and has brought more than a dozen therapeutic products to market in North America and Europe. From 1997 to 2007, he served as President and CEO of development stage companies Eligix, Inc. (merged with BioTransplant at $75M valuation), Genetix Pharmaceuticals (which has accomplished the long term correction of thalassemia major by a gene therapy brought into development by Mr. Ogier in 2001), and Arbios Systems Inc. He was previously Vice President of Marketing with Aastrom Biosciences, Inc., which he helped to bring public in 1997 (Nasdaq: ASTM), and earlier in his career held various product management, global marketing and business development positions within the Blood Therapy Group of Baxter Healthcare Corporation. Mr. Ogier’s industry experience spans development of small molecule drugs, monoclonal antibodies, growth factors, adult stem cell and immune cell therapies, gene therapies, bone marrow and solid organ transplantation, therapeutic medical devices and blood diagnostics with a focus on blood-related diseases including hematologic cancers, inflammatory / autoimmune diseases and genetic blood disorders. Mr. Ogier received his M.B.A. from the Yale School of Management and B.A. in chemistry magna cum laude from Williams College.
VP Biology and Preclinical Development
Dr. Jones joined Acetylon in September 2009 from EPIX Pharmaceuticals Inc., where he was Vice President of Biology and ADMET. Prior to EPIX, Dr. Jones held senior level positions in drug discovery and preclinical development for leading biotechnology companies including Director of Preclinical Development at ArQule Inc., Senior Director of Drug Discovery at Curis Inc., and Senior Director of Molecular Therapeutics and Cellular Biology at Creative BioMolecules Inc. Earlier in his career, Dr. Jones held multiple positions of increasing responsibility in the Department of Small Molecule Drug Discovery at Genetics Institute/Wyeth, now part of Pfizer. Dr. Jones is an author of dozens of peer-reviewed publications and multiple US patents. He maintains active membership in the American Society of Hematology, the American Association of Pharmaceutical Scientists, the Drug Information Association and The Society for Biomolecular Screening. He received his B.Sc. Honors Degree in chemistry and Ph.D. in bioorganic chemistry from Kings College, University of London, U.K., where he also engaged in post-doctoral research.
VP Chemistry and Manufacturing
Dr. van Duzer joined Acetylon in September 2009 from Mersana Therapeutics, Inc. where he was Vice President of Manufacturing and Pharmaceutical Sciences. Prior to Mersana, Dr. van Duzer held multiple positions in chemistry and manufacturing at ActivBiotics Corporation, advancing to the position of Vice President, Manufacturing. Before ActivBiotics, he was Director of Chemistry at Inotek Corporation and, earlier, advanced through multiple positions in the Inflammation Osteoarthritis Chemistry Research Group at Ciba-Geigy Corporation and Novartis Pharmaceuticals. Dr. van Duzer is the author of numerous peer-reviewed publications and an author of over 20 issued US drug patents. He received his B.A. with honors in chemistry from the University of Pennsylvania and his M.S. and PhD degrees in synthetic organic chemistry from Yale University.
VP Clinical Development
Dr. Wheeler joined Acetylon in November 2010 from Roche Pharmaceuticals, Inc, (Hoffmann-La Roche) where she was Site Head, Translational Medicine, Oncology and served earlier as Head, Signal Transduction I and Ad Interim Head, Roche Oncology Clinical Development. Prior to Roche, Dr. Wheeler was with AstraZeneca where she served as Vice President, Strategic Planning and Business Development, Oncology and Infection and previously in clinical development as Global Product Director Product Medical Director for the Emerging Product Team. She held multiple positions at PAREXEL International Corporation including Executive Director, Oncology Therapeutic Area Group and Medical Director. She was Clinical Director of the Bone Marrow Transplant Program at the Beth Israel Hospital in Boston, Massachusetts and was an Attending Physician and a Fellow at Beth Israel and the Dana-Farber Cancer Institute. Dr. Wheeler is a graduate of Bennington College and received her MD degree with honors from the Abraham Lincoln School of Medicine at the University of Illinois. She is Board certified in internal medicine, hematology and medical oncology, was an American Cancer Society Clinical Fellowship, and serves as Clinical Associate Professor of Medicine at Harvard Medical School.
Consulting Head of Regulatory Affairs
Ms. Shankle joined Acetylon in March 2010. She has more than 30 years of life sciences industry experience and since 1994 has managed a successful consulting practice providing regulatory, quality and project management services to the biopharmaceutical industry, spanning a broad range of products including recombinant proteins, glycoproteins, monoclonal antibodies, vaccines, peptides, complex carbohydrates, and biological devices. From 2005 to 2010, she was regulatory program manager and principal FDA liaison for the HDAC inhibitor romidepsin (Istodax, Celgene), which was recently approved for US market launch. Prior to starting her successful consulting practice, Ms. Shankle was the Director of Regulatory and Quality Affairs for Institute of Molecular Biology, Inc. and the Manager of Regulatory and Quality Assurance at Seragen, Inc.. Ms. Shankle received her B.S. in medical technology from University of Massachusetts in Amherst.
Consulting Head of Business Development
Dr. Hartmann has more than 20 years of experience in the pharmaceuticals industry focused in clinical research and development, program and portfolio management, business development and licensing. Since July, 2007 he has worked as an independent consultant in his fields of expertise. From 2005 to 2007, he served as Executive Vice President, Strategic and Corporate Development with Vertex Pharmaceuticals. Prior to joining Vertex, Dr. Hartmann held various positions at Novartis, most recently as Senior Vice President, Head Global Business Development and Licensing from 2000 to 2005 based in Basel. In his 9 years with Novartis, he also served as Vice President, Head Search and Evaluation and Vice President, Head Global Project Management. From 1994 to 1996 he was Vice President, Head Clinical Research and Development for Sandoz Pharmaceuticals Corporation and served as Vice President, Head Corporate Project Management for Sandoz Pharma AG. From 1982 to 1994, Dr. Hartmann served in a variety of roles in clinical R&D at Boehringer Ingelheim including Vice President, Medical Affairs for Boehringer Ingelheim Pharmaceuticals, Inc. He earned his B.S. in biology from Macalester College. He holds a Doctor of Medicine degree from the University of Bonn, Germany and has a degree in internal medicine.